专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08945620B2 Solid pharmaceutical compositions containing pregabalin 有权
标题翻译：含有普瑞巴林的固体药物组合物
公开(公告)号：US08945620B2
公开(公告)日：2015-02-03
申请号：US14181785
申请日：2014-02-17
申请人： Warner-Lambert Company LLC
发明人： Howard N. Bockbrader , Yun Hyung Cho , Steven Diaz Santiago , Majid Mahjour , Thomas Daniel Reynolds , Pushpa Ganapathi Shao , Zezhi Jesse Shao , Jiansheng Wan
IPC分类号： A61K9/22 , A61K47/32 , A61K9/00 , A61K31/197 , A61K47/34 , A61K9/20
CPC分类号： A61K47/32 , A61K9/0053 , A61K9/0065 , A61K9/141 , A61K9/146 , A61K9/2027 , A61K31/197 , A61K47/34 , A61K2039/542
摘要： A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
摘要翻译：描述了含有普瑞巴林的固体药物组合物。该组合物包括基质形成剂和溶胀剂，并且适合于每日一次的口服给药。示例性的基质形成剂包括聚乙酸乙烯酯和聚乙烯吡咯烷酮的混合物，示例性的溶胀剂包括聚乙烯吡咯烷酮的交联聚合物。

2. 发明申请

US20140012042A1 Calcium Dicarboxylate Ethers 审中-公开
标题翻译：二羧酸钙醚
公开(公告)号：US20140012042A1
公开(公告)日：2014-01-09
申请号：US14023912
申请日：2013-09-11
申请人： Warner-Lambert Company, LLC
发明人： Charles Larry Bisgaier , Roger Schofield Newton
IPC分类号： A61K31/194
CPC分类号： A61K31/194 , A61B5/7275 , A61K31/22 , A61K31/225 , A61K31/365 , A61K31/366 , A61K31/40 , A61K31/401 , A61K31/405 , A61K31/44 , C07C59/305 , A61K2300/00
摘要： The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases.
摘要翻译：本发明是一种药物组合物，其包含降低甘油三酯和升高的HDL的羧基烷基醚，以及抑制HMG-CoA还原酶的他汀类，从而降低LDL，所述组合物可用于治疗血管疾病。

3. 发明授权

US08623883B2 4-phenylamino-quinazolin-6-yl-amides 有权
标题翻译： 4-苯基氨基 - 喹唑啉-6-基 - 酰胺
公开(公告)号：US08623883B2
公开(公告)日：2014-01-07
申请号：US13914410
申请日：2013-06-10
申请人： Warner-Lambert Company LLC
发明人： Stephen Alan Fakhoury , Helen Tsenwhei Lee , Jessica Elizabeth Reed , Kevin Matthew Schlosser , Karen Elaine Sexton , Haile Tecle , Roy Thomas Winters
IPC分类号： A01N43/54 , A61K31/519 , C07D239/72 , C07D401/00
CPC分类号： C07D239/94 , C07D401/12 , C07D403/12
摘要： This invention provides quinazoline compounds of the formula: wherein: R1 is halo; R2 is H or halo; R3 is a) C1-C3 alkyl, optionally substituted by halo; or b) —(CH2)n-morpholino, —(CH2)n-piperidine, —(CH2)n-piperazine, —(CH2)n-piperazine-N(C1-C3 alkyl), —(CH2)n-pyrrolidine, or —(CH2)n-imidazole; n is 1 to 4; R4 is —(CH2)m-Het; Het is morpholine, piperidine, piperazine, piperazine-N(C1-C3 alkyl), imidazole, pyrrolidine, azepane, 3,4-dihydro-2H-pyridine, or 3,6-dihydro-2H-pyridine, each optionally substituted by alkyl, halo, OH, NH2, NH(C1-C3 alkyl) or N(C1-C3 alkyl)2; m is 1-3; and X is O, S or NH; or a pharmaceutically acceptable salt thereof, as well as processes and intermediate compounds for making them, useful pharmaceutical compositions and methods of using the compounds in the treatment of proliferative diseases.
摘要翻译：本发明提供下式的喹唑啉化合物：其中：R1是卤素; R2是H或卤素; R3是a）任选被卤素取代的C 1 -C 3烷基; 或（b） - （CH 2）n - 吗啉代， - （CH 2）n - 哌啶， - （CH 2）n - 哌嗪， - （CH 2）n - 哌嗪-N（C 1 -C 3烷基）， - （CH 2），或 - （CH 2）n - 咪唑; n为1〜4; R4是 - （CH2）m-Het; Het是吗啉，哌啶，哌嗪，哌嗪-N（C 1 -C 3烷基），咪唑，吡咯烷，氮杂环庚烷，3,4-二氢-2H-吡啶或3,6-二氢-2H-吡啶，各自任选被烷基，卤素，OH，NH 2，NH（C 1 -C 3烷基）或N（C 1 -C 3烷基）2; m为1-3; X为O，S或NH; 或其药学上可接受的盐，以及制备它们的方法和中间体化合物，有用的药物组合物和使用该化合物治疗增殖性疾病的方法。

4. 发明授权

US08563750B2 Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylmino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) 有权
标题翻译： [R-（R *，R *）] - 2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] -1H - 吡咯-1-庚酸钙盐（2:1）
公开(公告)号：US08563750B2
公开(公告)日：2013-10-22
申请号：US13214559
申请日：2011-08-22
申请人： Aeri Park , Timothy A Woods
发明人： Aeri Park , Timothy A Woods
IPC分类号： C07D207/00
CPC分类号： C07D207/34
摘要： Novel forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form XX, Form XXI, Form XXII, Form XXIII, Form XXIV, Form XXV, Form XXVI, Form XXVII, Form XXVIII, Form XXIX, and Form XXX, characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (BPH) and Alzheimer's disease.
摘要翻译： [R-（R *，R *）] -2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 指定为XX型，XXI型，XXII型，XXIII型，XXIV型，XXV型，XXVI型，XXVII型，XXVIII型，XXX型和XXX型的1H-吡咯-1-庚酸半钙盐，其特征在于它们的X 描述了射线粉末衍射，固体NMR和/或拉曼光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症，高胆固醇血症，骨质疏松症，良性前列腺增生症（BPH ）和阿尔茨海默病。

5. 发明申请

US20130102675A1 Solid Pharmaceutical Compositions Containing Pregabalin 审中-公开
公开(公告)号：US20130102675A1
公开(公告)日：2013-04-25
申请号：US13706971
申请日：2012-12-06
申请人： Warner-Lambert Company LLC
发明人： Howard N. Bockbrader , Yun Hyung Cho , Steven Diaz Santiago , Majid Mahjour , Thomas Daniel Reynolds , Pushpa Ganapathi Shao , Zezhi Jesse Shao , Jiansheng Wan
IPC分类号： A61K31/197 , A61K47/34
CPC分类号： A61K47/32 , A61K9/0053 , A61K9/0065 , A61K9/141 , A61K9/146 , A61K9/2027 , A61K31/197 , A61K47/34 , A61K2039/542
摘要： A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

6. 发明申请

US20120244167A1 ANTIBODIES TO M-CSF 审中-公开
标题翻译：抗体对M-CSF
公开(公告)号：US20120244167A1
公开(公告)日：2012-09-27
申请号：US13458820
申请日：2012-04-27
申请人： Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
发明人： Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
IPC分类号： A61K39/395 , A61P29/00 , A61P35/00 , C12N1/19 , A61P9/00 , C12N5/16 , C12N5/10 , C12N1/21 , C07K16/24 , A61P25/00
CPC分类号： C07K16/243 , A61K38/193 , A61K39/395 , A61K2039/505 , C07K16/24 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G06Q30/02 , G06Q30/0601 , G06Q40/04 , G06Q50/12 , Y02A50/412
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.
摘要翻译：本发明涉及特异性结合M-CSF，优选人M-CSF的抗体及其抗原结合部分，其功能是抑制M-CSF。本发明还涉及人抗M-CSF抗体及其抗原结合部分。本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。本发明还涉及制备人抗M-CSF抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。

7. 发明申请

US20110142925A1 Film Coating For Tablets And Caplets 有权
标题翻译：片剂和胶囊的薄膜包衣
公开(公告)号：US20110142925A1
公开(公告)日：2011-06-16
申请号：US13034928
申请日：2011-02-25
申请人： Robert Anthony Scott , Dominique Cade , Frederic Hoehn , Ewart Thomas Cole
发明人： Robert Anthony Scott , Dominique Cade , Frederic Hoehn , Ewart Thomas Cole
IPC分类号： A61K9/48
CPC分类号： A61K9/4808 , A61K9/2072 , A61K9/2866
摘要： The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions.
摘要翻译：本发明涉及用于固体剂型如片剂或囊片的新型涂料组合物，涂覆有该组合物的固体剂型，以及制备所述涂料组合物的方法。

8. 发明申请

US20090105349A1 ANDROGEN MODULATORS 审中-公开
标题翻译：安德鲁调制器
公开(公告)号：US20090105349A1
公开(公告)日：2009-04-23
申请号：US11572760
申请日：2005-08-08
申请人： Nicole Chantel Barvian , Daniel Yunlong Du , Lain-Yen Hu , Donna Michele Iula , Bruce Allen Lefker , Huangshu Lei , Raj Kumar Raheja , Yvonne Dorothy Smith
发明人： Nicole Chantel Barvian , Daniel Yunlong Du , Lain-Yen Hu , Donna Michele Iula , Bruce Allen Lefker , Huangshu Lei , Raj Kumar Raheja , Yvonne Dorothy Smith
IPC分类号： A61K31/135 , A61P5/26
CPC分类号： A61K31/275
摘要： The present invention is directed to the discovery of a new class of androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease sebum secretion and to stimulate hair growth.
摘要翻译：本发明涉及新型雄激素受体调节剂的发现。本发明的其它方面涉及这些化合物减少皮脂分泌和刺激毛发生长的用途。

9. 发明申请

US20090029995A1 HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS 审中-公开
标题翻译： HETERO BIARYL衍生物作为基质金属蛋白酶抑制剂
公开(公告)号：US20090029995A1
公开(公告)日：2009-01-29
申请号：US11564453
申请日：2006-11-29
申请人： Amy Mae Bunker , Mark Anthony Morris , Patrick Michael O'Brien , Michael William Wilson
发明人： Amy Mae Bunker , Mark Anthony Morris , Patrick Michael O'Brien , Michael William Wilson
IPC分类号： A61K31/5377 , C07D257/04 , A61K31/41 , C07D277/20 , A61K31/433 , A61K31/44 , A61K31/4245 , A61K31/421 , A61P11/00 , A61P19/00 , A61P9/00 , C07D263/30 , C07D271/06 , C07D213/02 , C07D285/06 , A61K31/426 , C07D295/00
CPC分类号： C07D257/04 , C07D231/12 , C07D233/56 , C07D249/08 , C07D271/10 , C07D271/107 , C07D285/12 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D405/12 , C07D409/06 , C07D413/10 , C07D417/10 , C07D417/12
摘要： This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, S, T, U, V, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions and methods of treating diseases.
摘要翻译：本发明提供由式I定义的化合物或其药学上可接受的盐，其中R 1，Q，S，T，U，V和R 2如说明书中所定义。本发明还提供了治疗疾病的药物组合物和方法。

10. 发明申请

US20080293715A1 Therapeutic Pyrazolo[3,4-b]Pyridines and Indazoles 审中-公开
标题翻译：治疗性吡唑并[3,4-b]吡啶类和吲唑类
公开(公告)号：US20080293715A1
公开(公告)日：2008-11-27
申请号：US12185419
申请日：2008-08-04
申请人： Robert M. Schelkun , Po-Wai Yuen
发明人： Robert M. Schelkun , Po-Wai Yuen
IPC分类号： A61K31/416 , C07D403/12 , C07D401/12 , C07D413/12 , C07D413/14 , A61K31/5377 , A61K31/454
CPC分类号： C07D231/56 , C07D401/04 , C07D403/12 , C07D413/12 , C07D471/04
摘要： The present invention provides for compounds of Formula I: wherein R2, R3, R4, R5, R6, R7, X, and L have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of central nervous disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
摘要翻译：本发明提供式I化合物：其中R2，R3，R4，R5，R6，R7，X和L具有说明书中定义的任何值及其药学上可接受的盐，其可用作治疗中枢神经障碍和包括注意力缺陷多动障碍，神经性疼痛，尿失禁，焦虑，抑郁和精神分裂症以及纤维肌痛的病症。还提供了包含一种或多种式I化合物的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式